APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7222-7231

  Leonard, Brandon ^a,b   Hart, Steven N ^c   Burns, Michael B ^a,b   Carpenter, Michael A ^a,b   Temiz, Nuri A ^a,b   Rathore, Anurag ^a,b   Vogel, Rachel I ^b   Nikas, Jason B ^b   Law, Emily K ^a,b   Brown, William L ^a,b   Li, Ying ^c   Zhang, Yuji ^c   Maurer, Matthew J ^c   Oberg, Ann L ^c   Cunningham, Julie M ^d   Shridhar, Viji ^d   Bell, Debra A ^d   April, Craig ^g   Bentley, David ^g   Bibikova, Marina ^g   Cheetham, R Keira ^g   Fan, Jian Bing ^g   Grocock, Russell ^g   Humphray, Sean ^g   Kingsbury, Zoya ^g   Peden, John ^g   Chien, Jeremy ^e   Swisher, Elizabeth M ^f   Hartmann, Lynn C ^d   Kalli, Kimberly R ^d   Goode, Ellen L ^d   Sicotte, Hugues ^d   Kaufmann, Scott H ^c,d   Harris, Reuben S ^a,b   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d Mayo Clinic Cancer Center   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g ILLUMINA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; DINUCLEOTIDE;

APOBEC3B GENE; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; DEAMINATION; DNA DAMAGE; DNA REPAIR; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; MUTAGENESIS; MUTATIONAL ANALYSIS; OVARY CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RNA SEQUENCE; TUMOR GENE; UPREGULATION;

CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; CYTIDINE DEAMINASE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENOMICS; HUMANS; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RNA, MESSENGER; UP-REGULATION;

EID: 84891276148     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1753     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
3. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:18032-7.
4. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev 2007;7:573-84.
5. Markman M. Antineoplastic agents in the management of ovarian cancer: Current status and emerging therapeutic strategies. Trends Pharmacol Sci 2008;29:515-9.
6. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15.
7. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013;494:366-70.
8. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012;287:40875-83.
9. Conticello SG. The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008;9:229.
10. Pasqualucci L, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008;40:108-12.
11. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci U S A 1995;92:8483-7.
12. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, et al. Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003;197:1173-81.
13. Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009;16:232-45.
14. Robbiani DF, Nussenzweig MC. Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 2013;8:79-103.
15. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012;109:3879-84.
16. Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012;26:1383-90.
17. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
18. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
19. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: Implications for HIV-1 restriction. Nucleic Acids Res 2010;38:4274-84.
20. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 2010;17:222-9.
21. Hong GF. Sequencing of large double-stranded DNA using the dideoxy sequencing technique. Biosci Rep 1982;2:907-12.
22. Smith NL, Welcsh P, Press JZ, Agnew KJ, Garcia R, Swisher EM. E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium. Genes Chromosomes Cancer 2012;51:1054-62.
23. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 2006;34:89-95.
24. Stenglein MD, Harris RS. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem 2006;281:16837-41.
25. Stenglein MD, Matsuo H, Harris RS. Two regions within the aminoterminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol 2008;82:9591-9.
26. Pak V, Heidecker G, Pathak VK, Derse D. The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol 2011;85:8538-47.
27. Lackey L, Demorest ZL, Land AM, Hultquist JF, Brown WL, Harris RS. APOBEC3B and AID have similar nuclear import mechanisms. J Mol Biol 2012;419:301-14.
28. Lackey L, Law EK, Brown WL, Harris RS. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 2013;12:762-72.
29. Rausch JW, Chelico L, Goodman MF, Le Grice SF. Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J Biol Chem 2009;284:7047-58.
30. Kohli RM, Maul RW, Guminski AF, McClure RL, Gajula KS, Saribasak H, et al. Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem 2010;285:40956-64.
31. Wang M, Rada C, Neuberger MS. Altering the spectrum of immunoglobulin V gene somatic hypermutation by modifying the active site of AID. J Exp Med 2010;207:141-53.
32. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013;45:977-83.
33. Carpenter MA, Li M, Rathore A, Lackey L, Law EK, Land AM, et al. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem 2012;287: 34801-8.
34. Wijesinghe P, Bhagwat AS. Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res 2012;40:9206-17.
35. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2012;2: 806.
36. Kim N, Mudrak SV, Jinks-Robertson S. The dCMP transferase activity of yeast Rev1 is biologically relevant during the bypass of endogenously generated AP sites. DNA Repair (Amst) 2011;10: 1262-71.
37. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2013;2:e00534.
38. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007;76:1-22.
39. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013;45:970-6.
40. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.